Ergoteles’s Exagen XGN Stock Holding History

Ergoteles’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-48,558	Closed	-$132K	–	1946
2022 Q3	$132K	Sell	48,558 -1,542	-3%	-$8.6K	﹤0.01%	1306
2022 Q2	$288K	Buy	+50,100	New	+$292K	0.01%	1126

Other funds holding XGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Ergoteles's XGN Position: Q4 2022 in Review

Ergoteles sold out of Exagen (XGN) in Q4 2022, closing a stake of 48,558 shares — an estimated $132K sold.

Ergoteles first reported a position in XGN in Q2 2022 and held it in 2 quarters. The position peaked at $288K in Q2 2022. 31 funds tracked by Wall St. Rank hold XGN as of Q4 2022.

Ergoteles reported no remaining Exagen position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 48,558 Exagen shares in Q4 2022, an estimated $132K.
Ergoteles first reported a position in Exagen in Q2 2022 and held it in 2 quarters.
Ergoteles's Exagen position peaked at $288K in Q2 2022.
31 funds tracked by Wall St. Rank held Exagen as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.